冠心病心律不齐临床采用胺碘酮联合美托洛尔效果研究探讨

Study on the Clinical Effect of Amiodarone Combined with Metoprolol in Patients with Coronary Heart Ddisease and Arrhythmia

目的探讨分析冠心病心律不齐临床采用胺碘酮联合美托洛尔效果。方法该次采用实验性研究,筛选病例时间2017年2月—2018年2月,共筛选符合标准的114例,按照数字随机法分成两组,参照组在常规治疗的基础上使用胺碘酮,研究组此基础上采用胺碘酮联合美托洛尔,对两组患者治疗前后临床血压,心率,左心室射血分数指标进行统计比较,并统计两组治疗期间血脂各项指标(TG、TC、LDL-C)变化以及不良反应发生率对比。结果两组实施治疗后,两组实施治疗后,研究组患者舒张压(70.19±4.28)mmHg,收缩压(116.87±4.73)mmHg,心率(76.31±9.79)次/min,左心室射血分数(35.03±5.11)%,参照组患者舒张压(90.11±4.18)mmHg,收缩压(130.76±7.11)mmHg,心率(91.22±10.18)次/min,左心室射血分数(29.17±5.06)%,组间比较差异有统计学意义(t=9.117、8.972、9.063、9.164,P<0.05)。研究组临床接受治疗期间不良反应发生率为5.26%,参照组临床接受治疗期间不良反应发生率为14.04%,两组比较差异有统计学意义(χ~2=9.736,P<0.05)。研究组治疗后TG (1.33±0.55)mmol/L、TC(3.87±1.09)mmol/L、LDL-C(2.46±1.18)mmol/L,参照组治疗后TG(1.95±0.83)mmol/L、TC(4.55±1.52)mmol/L、LDL-C(2.81±1.07)mmol/L,组间比较差异有统计学意义(t=8.926、8.093、8.116,P<0.05)。结论冠心病心律不齐临床采用胺碘酮联合美托洛尔临床的治疗效果显著,不良反应少,大大提高治疗的安全性,值得推广。

Objective To investigate the clinical effect of amiodarone combined with metoprolol in the diagnosis of arrhythmia in coronary heart disease.Methods This time,an experimental study was conducted to screen the case time from February2017 to February 2018.A total of 114 patients who met the criteria were screened and divided into two groups according to the numerical randomization method.The reference group used amiodarone on the basis of conventional treatment.On the basis of this,the study group used amiodarone combined with metoprolol to compare the clinical blood pressure,heart rate and left ventricular ejection fraction before and after treatment,and to compare the blood lipid indexes(TG,TC,LDL-C)changes and the incidence of adverse reactions.Results After treatment in both groups,the patients in the study group had diastolic blood pressure(70.19±4.28)mmHg,systolic blood pressure(116.87±4.73)mmHg,heart rate(76.31±9.79)times/min,left ventricular ejection fraction after treatment(35.03±5.11)%,diastolic blood pressure(90.11±4.18)mmHg,systolic blood pressure(130.76±7.11)mmHg,heart rate(91.22±10.18)times/min,left ventricular ejection fraction(29.17±5.06)%,the difference between the two groups was statistically significant(t=9.117,8.972,9.063,9.164,P<0.05).The incidence of adverse reactions during the clinical treatment of the study group was 5.26%,and the incidence of adverse reactions during the clinical treatment of the reference group was 14.04%.The difference between the two groups was statistically significant(χ^2=9.736,P<0.05).TG(1.33±0.55)mmol/L,TC(3.87±1.09)mmol/L,and LDL-C(2.46±1.18)mmol/L after treatment in the study group,TG(1.95±0.83)mmol/L after treatment in the reference group,TC(4.55± 1.52)mmol/L,LDL-C(2.81±1.07)mmol/L,the difference between the groups was statistically significant(t=8.926,8.093,8.116,P<0.05).Conclusion The clinical treatment of arrhythmia in coronary heart disease with amiodarone combined with metoprolol is significant,with fewer adverse reactions,which greatly improves the safety of treatment and is worthy of promotion.